

Emphysema Treatment Market: Medication Segment Leads with Cost-Effective Solutions, Holding Largest Share

PORTLAND, OR, UNITED STATES, January 6, 2025 /EINPresswire.com/ -- The global <u>emphysema</u> <u>treatment market</u> is experiencing significant growth, driven by various factors including the rising prevalence of the disease, increasing smoking rates, and advancements in healthcare technology. Valued at \$6.3 billion in 2022, the market is projected to reach \$8.7 billion by 2032, growing at a CAGR of 3.3% from 2023 to 2032.

Key Market Insights

• Medication Segment Dominance: The medication segment was the largest in 2022, favored for its cost-effectiveness and common use as a first-line treatment.

- Centriacinar Emphysema Growth: The centriacinar segment, primarily linked to smoking, is anticipated to grow the fastest.
- Rise of Homecare: Homecare emerged as the leading end-user segment in 2022, bolstered by the availability of portable treatment devices that facilitate home-based care.
- Regional Highlights:
- North America led in market share due to advanced healthcare systems and robust R&D activities.
- The Asia-Pacific region is expected to show the highest growth rates, driven by deteriorating air quality and increasing cases of chronic obstructive pulmonary disease (COPD).

Emphysema Overview

Emphysema is a chronic lung condition characterized by the destruction of alveoli, resulting in decreased lung elasticity and difficulty breathing. Key symptoms include:

- Shortness of breath
- Chronic coughing
- Wheezing
- Chest tightness
- **Primary Causes**
- Long-term exposure to irritants such as cigarette smoke and air pollution.

• Genetic predispositions.

Market Drivers

- 1. Rising Prevalence of Emphysema:
- Over 3 million Americans are diagnosed with emphysema.
- Smoking remains a primary cause, with significant adult smoking rates reported.
- Increasing air pollution exacerbates the condition, particularly in South Asia.
- 2. Improving Healthcare Infrastructure:
- Enhanced diagnostic capabilities (e.g., HRCT scanners).
- Development of multidisciplinary care teams for personalized treatment.
- 3. Technological Advancements:
- Adoption of minimally invasive procedures like bronchoscopic lung volume reduction.
- Availability of advanced inhalers and oxygen therapy devices.
- 4. R&D Innovations:
- Introduction of new therapies such as Trelegy Ellipta and emerging treatments like ensifentrine.

Market Challenges

- High Treatment Costs: Surgical interventions and oxygen therapies can be prohibitively expensive.
- Economic Disparities: Developing countries face barriers in accessing advanced treatments due to financial constraints.

Segments Overview

By Treatment Type

- Medication: Most widely used due to affordability.
- Oxygen Therapy: Essential for advanced cases.
- Surgery: Typically reserved for severe cases.

Ву Туре

- Centriacinar Emphysema: Common among smokers.
- Panacinar Emphysema: Associated with genetic factors.

By End User

- Homecare: Gaining traction due to user-friendly devices.
- Hospitals and Specialty Centers: Cater to severe cases needing advanced care.

Recent Developments

- AstraZeneca launched a Phase III trial for Breztri Aerosphere in March 2024.
- Verona Pharma secured \$400 million for commercializing ensifentrine in January 2024.
- Inogen expanded its portfolio by acquiring Physio-Assist in September 2023.
 Key Players

Leading companies in this market include:

- AstraZeneca
- Boehringer Ingelheim
- GlaxoSmithKline
- Novartis AG

- Teva Pharmaceuticals
- Verona Pharma

Future Outlook

The emphysema treatment market is set for steady growth due to:

- Expanding R&D pipelines.
- Continuous technological advancements.
- Increased awareness and improved diagnostic capabilities.

Key Takeaways

- Enhanced healthcare access and innovative therapies are crucial for bridging treatment gaps.
- Addressing cost challenges will unlock further market potential, particularly in emerging economies.

This comprehensive analysis underscores the dynamic nature of the emphysema treatment market, highlighting both opportunities and challenges that stakeholders must navigate moving forward.

David Correa Allied Market Research +1 800-792-5285 email us here Visit us on social media: Facebook X

This press release can be viewed online at: https://www.einpresswire.com/article/774384946

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire[™], tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2025 Newsmatics Inc. All Right Reserved.